FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328107864> ?p ?o ?g. }

• W4328107864 endingPage "1770.e7" @default.
• W4328107864 startingPage "1759" @default.
• W4328107864 abstract "BackgroundThe phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma. Patients from ANDHI DB could join the 56-week ANDHI in Practice (IP) single-arm, open-label extension substudy.ObjectiveAssess potential for standard-of-care background medication reductions while maintaining asthma control with benralizumab.MethodsFollowing ANDHI DB completion, eligible adults were enrolled in ANDHI IP. After an 8-week run-in with benralizumab, there were 5 visits to potentially reduce background asthma medications for patients achieving and maintaining protocol-defined asthma control with benralizumab. Main outcome measures for non–oral corticosteroid (OCS)-dependent patients were the proportions with at least 1 background medication reduction (ie, lower inhaled corticosteroid dose, background medication discontinuation) and the number of adapted Global Initiative for Asthma (GINA) step reductions at end of treatment (EOT). Main outcomes for OCS-dependent patients were reductions in daily OCS dosage and proportion achieving OCS dosage of 5 mg or lower at EOT.ResultsFor non–OCS-dependent patients, 53.3% (n = 208 of 390) achieved at least 1 background medication reduction, increasing to 72.6% (n = 130 of 179) for patients who maintained protocol-defined asthma control at EOT. A total of 41.9% (n = 163 of 389) achieved at least 1 adapted GINA step reduction, increasing to 61.8% (n = 110 of 178) for patients with protocol-defined EOT asthma control. At ANDHI IP baseline, OCS dosages were 5 mg or lower for 40.4% (n = 40 of 99) of OCS-dependent patients. Of OCS-dependent patients, 50.5% (n = 50 of 99) eliminated OCS and 74.7% (n = 74 of 99) achieved dosages of 5 mg or lower at EOT.ConclusionsThese findings demonstrate benralizumab’s ability to improve asthma control, thereby allowing background medication reduction. The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma. Patients from ANDHI DB could join the 56-week ANDHI in Practice (IP) single-arm, open-label extension substudy. Assess potential for standard-of-care background medication reductions while maintaining asthma control with benralizumab. Following ANDHI DB completion, eligible adults were enrolled in ANDHI IP. After an 8-week run-in with benralizumab, there were 5 visits to potentially reduce background asthma medications for patients achieving and maintaining protocol-defined asthma control with benralizumab. Main outcome measures for non–oral corticosteroid (OCS)-dependent patients were the proportions with at least 1 background medication reduction (ie, lower inhaled corticosteroid dose, background medication discontinuation) and the number of adapted Global Initiative for Asthma (GINA) step reductions at end of treatment (EOT). Main outcomes for OCS-dependent patients were reductions in daily OCS dosage and proportion achieving OCS dosage of 5 mg or lower at EOT. For non–OCS-dependent patients, 53.3% (n = 208 of 390) achieved at least 1 background medication reduction, increasing to 72.6% (n = 130 of 179) for patients who maintained protocol-defined asthma control at EOT. A total of 41.9% (n = 163 of 389) achieved at least 1 adapted GINA step reduction, increasing to 61.8% (n = 110 of 178) for patients with protocol-defined EOT asthma control. At ANDHI IP baseline, OCS dosages were 5 mg or lower for 40.4% (n = 40 of 99) of OCS-dependent patients. Of OCS-dependent patients, 50.5% (n = 50 of 99) eliminated OCS and 74.7% (n = 74 of 99) achieved dosages of 5 mg or lower at EOT. These findings demonstrate benralizumab’s ability to improve asthma control, thereby allowing background medication reduction." @default.
• W4328107864 created "2023-03-22" @default.
• W4328107864 creator A5000097023 @default.
• W4328107864 creator A5000178464 @default.
• W4328107864 creator A5000947135 @default.
• W4328107864 creator A5001116765 @default.
• W4328107864 creator A5001367339 @default.
• W4328107864 creator A5002162144 @default.
• W4328107864 creator A5002223089 @default.
• W4328107864 creator A5002985531 @default.
• W4328107864 creator A5003529451 @default.
• W4328107864 creator A5003702263 @default.
• W4328107864 creator A5004292301 @default.
• W4328107864 creator A5004648556 @default.
• W4328107864 creator A5005069896 @default.
• W4328107864 creator A5005080145 @default.
• W4328107864 creator A5005433296 @default.
• W4328107864 creator A5006590661 @default.
• W4328107864 creator A5006680780 @default.
• W4328107864 creator A5006922284 @default.
• W4328107864 creator A5008025085 @default.
• W4328107864 creator A5008229353 @default.
• W4328107864 creator A5008835693 @default.
• W4328107864 creator A5008993981 @default.
• W4328107864 creator A5009247348 @default.
• W4328107864 creator A5009563289 @default.
• W4328107864 creator A5009891434 @default.
• W4328107864 creator A5010944670 @default.
• W4328107864 creator A5012076399 @default.
• W4328107864 creator A5013045967 @default.
• W4328107864 creator A5013346756 @default.
• W4328107864 creator A5015437404 @default.
• W4328107864 creator A5016060492 @default.
• W4328107864 creator A5016471273 @default.
• W4328107864 creator A5016492321 @default.
• W4328107864 creator A5016521386 @default.
• W4328107864 creator A5016632165 @default.
• W4328107864 creator A5016817455 @default.
• W4328107864 creator A5016962663 @default.
• W4328107864 creator A5017046428 @default.
• W4328107864 creator A5017092046 @default.
• W4328107864 creator A5017756139 @default.
• W4328107864 creator A5017844953 @default.
• W4328107864 creator A5018421075 @default.
• W4328107864 creator A5018517139 @default.
• W4328107864 creator A5018947556 @default.
• W4328107864 creator A5019798684 @default.
• W4328107864 creator A5020260918 @default.
• W4328107864 creator A5020629887 @default.
• W4328107864 creator A5020771393 @default.
• W4328107864 creator A5020869279 @default.
• W4328107864 creator A5021025712 @default.
• W4328107864 creator A5022730289 @default.
• W4328107864 creator A5023604012 @default.
• W4328107864 creator A5024236618 @default.
• W4328107864 creator A5026426001 @default.
• W4328107864 creator A5026657106 @default.
• W4328107864 creator A5027144208 @default.
• W4328107864 creator A5028666592 @default.
• W4328107864 creator A5029422348 @default.
• W4328107864 creator A5029434875 @default.
• W4328107864 creator A5029749429 @default.
• W4328107864 creator A5030399868 @default.
• W4328107864 creator A5030456446 @default.
• W4328107864 creator A5031635005 @default.
• W4328107864 creator A5032206464 @default.
• W4328107864 creator A5032494504 @default.
• W4328107864 creator A5034740825 @default.
• W4328107864 creator A5035374713 @default.
• W4328107864 creator A5035570881 @default.
• W4328107864 creator A5036017418 @default.
• W4328107864 creator A5036061489 @default.
• W4328107864 creator A5036532466 @default.
• W4328107864 creator A5037101918 @default.
• W4328107864 creator A5037945336 @default.
• W4328107864 creator A5038309064 @default.
• W4328107864 creator A5038824744 @default.
• W4328107864 creator A5039442977 @default.
• W4328107864 creator A5039468195 @default.
• W4328107864 creator A5040230220 @default.
• W4328107864 creator A5040477967 @default.
• W4328107864 creator A5040742684 @default.
• W4328107864 creator A5041353322 @default.
• W4328107864 creator A5041567751 @default.
• W4328107864 creator A5041568994 @default.
• W4328107864 creator A5042285373 @default.
• W4328107864 creator A5043268741 @default.
• W4328107864 creator A5043459938 @default.
• W4328107864 creator A5043732814 @default.
• W4328107864 creator A5044325715 @default.
• W4328107864 creator A5046119332 @default.
• W4328107864 creator A5046731249 @default.
• W4328107864 creator A5047449018 @default.
• W4328107864 creator A5047503506 @default.
• W4328107864 creator A5048057602 @default.
• W4328107864 creator A5048952305 @default.
• W4328107864 creator A5050506459 @default.
• W4328107864 creator A5051845249 @default.

• next